PURPOSE OF REVIEW: This review focuses on advances in current and novel treatment approaches in multiple sclerosis. RECENT FINDINGS: New therapeutic approaches in multiple sclerosis are emerging. Orally available treatment strategies are more acceptable for patients and may improve adherence to therapy. An oral formulation of glatiramer acetate failed to demonstrate efficacy in a clinical trial, but other promising compounds are on the horizon, such as FTY720. Advances are currently being made in use of therapeutic monoclonal antibodies that specifically target key molecules involved in the immunopathogenesis of multiple sclerosis. Natalizumab directed against the adhesion molecule very late antigen-4 represents the first specific antibody to be added to our therapeutic armamentarium for multiple sclerosis. Further evidence that immunomodulation should be initiated as early as possible has been reported. SUMMARY: Treatment of multiple sclerosis has changed dramatically over the past decade. Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail.
PURPOSE OF REVIEW: This review focuses on advances in current and novel treatment approaches in multiple sclerosis. RECENT FINDINGS: New therapeutic approaches in multiple sclerosis are emerging. Orally available treatment strategies are more acceptable for patients and may improve adherence to therapy. An oral formulation of glatiramer acetate failed to demonstrate efficacy in a clinical trial, but other promising compounds are on the horizon, such as FTY720. Advances are currently being made in use of therapeutic monoclonal antibodies that specifically target key molecules involved in the immunopathogenesis of multiple sclerosis. Natalizumab directed against the adhesion molecule very late antigen-4 represents the first specific antibody to be added to our therapeutic armamentarium for multiple sclerosis. Further evidence that immunomodulation should be initiated as early as possible has been reported. SUMMARY: Treatment of multiple sclerosis has changed dramatically over the past decade. Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail.
Authors: Huizhi Wang; Jonathan Brown; Carlos A Garcia; Yunan Tang; Manjunatha R Benakanakere; Terrance Greenway; Pascale Alard; Denis F Kinane; Michael Martin Journal: J Immunol Date: 2010-12-15 Impact factor: 5.422
Authors: C E Teunissen; A Petzold; J L Bennett; F S Berven; L Brundin; M Comabella; D Franciotta; J L Frederiksen; J O Fleming; R Furlan; R Q Hintzen; S G Hughes; M H Johnson; E Krasulova; J Kuhle; M C Magnone; C Rajda; K Rejdak; H K Schmidt; V van Pesch; E Waubant; C Wolf; G Giovannoni; B Hemmer; H Tumani; F Deisenhammer Journal: Neurology Date: 2009-12-01 Impact factor: 9.910
Authors: Dongxu Zhai; Frankie H F Lee; Cheryl D'Souza; Ping Su; Shouping Zhang; Zhengping Jia; Li Zhang; Albert H C Wong; Fang Liu Journal: Ann Clin Transl Neurol Date: 2015-02-19 Impact factor: 4.511
Authors: Christopher S Garris; Linfeng Wu; Swati Acharya; Ahmet Arac; Victoria A Blaho; Yingxiang Huang; Byoung San Moon; Robert C Axtell; Peggy P Ho; Gary K Steinberg; David B Lewis; Raymond A Sobel; David K Han; Lawrence Steinman; Michael P Snyder; Timothy Hla; May H Han Journal: Nat Immunol Date: 2013-09-29 Impact factor: 25.606
Authors: Xiujuan Zhang; Annie C Bowles; Julie A Semon; Brittni A Scruggs; Shijia Zhang; Amy L Strong; Jeffrey M Gimble; Bruce A Bunnell Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240